Development of an L6 myoblast in vitro model of moniliformin toxicosis

作者: R. Reams , H. L. Thacker , M. Novilla , D. Laska , J. Horn

DOI: 10.1007/BF00439121

关键词:

摘要: L6 myoblasts were used as an in vitro model to investigate the role of moniliformin and its interaction with monensin turkey knockdown syndrome sudden death syndromes poultry. Cell viability microscopic ultrastructural alterations noted cultured presence (0.0–0.3 μg/μl) compared those observed parallel cultures also containing one following compounds: selenium (0–0.004 ng/μl), thiamine (0–0.3 μg/μl), or pyruvate (0–0.46 μg/μl). Marked dilation RER, membranous whorls, glycogen deposition, membrane-bound cytoplasmic inclusions necrosis exposed 0.03/2-0.30 μg moniliformin/μl medium. Supplementation medium pyruvate, selenium, provided significant protection cells 0.0–0.3 μg/μl 0.0–0.15 moniliformin/μl, respectively. Dose-dependent differences protein ATP production not detected. Myoblasts grown 0–0.15 7.5–50.0 μM A23187, beauvericin had degrees cytotoxicity similar receiving only ionophore. a useful toxicosis. The findings this study suggest due may be part oxidative damage altered metabolism, that does predispose ionophore This supports results vivo investigations poultry do act synergistically induce

参考文章(29)
Emeteria Yatco-Manzo, Frances Roddy, Ralph G. Yount, David E. Metzler, The Catalytic Decarboxylation of Pyruvate by Thiamine Journal of Biological Chemistry. ,vol. 234, pp. 733- 737 ,(1959) , 10.1016/S0021-9258(18)70164-6
Novilla Mn, The veterinary importance of the toxic syndrome induced by ionophores. Veterinary and Human Toxicology. ,vol. 34, pp. 66- 70 ,(1992)
H R Burmeister, A Ciegler, R F Vesonder, Moniliformin, a metabolite of Fusarium moniliforme NRRL 6322: purification and toxicity. Applied and Environmental Microbiology. ,vol. 37, pp. 11- 13 ,(1979) , 10.1128/AEM.37.1.11-13.1979
W.Thomas Shier, Daniel J. DuBourdieu, Sodium- and calcium-de-endent steps in the mechanism of neonatal rat cardiac myocyte killing by lonophores Toxicology and Applied Pharmacology. ,vol. 116, pp. 38- 46 ,(1992) , 10.1016/0041-008X(92)90142-F
H R Burmeister, M D Grove, W F Kwolek, Moniliformin and butenolide: effect on mice of high-level, long-term oral intake. Applied and Environmental Microbiology. ,vol. 40, pp. 1142- 1144 ,(1980) , 10.1128/AEM.40.6.1142-1144.1980
P S Gathercole, P G Thiel, J H S Hofmeyr, Inhibition of pyruvate dehydrogenase complex by moniliformin. Biochemical Journal. ,vol. 233, pp. 719- 723 ,(1986) , 10.1042/BJ2330719
C J Rabie, W F Marasas, P G Thiel, A Lübben, R Vleggaar, Moniliformin production and toxicity of different Fusarium species from Southern Africa. Applied and Environmental Microbiology. ,vol. 43, pp. 517- 521 ,(1982) , 10.1128/AEM.43.3.517-521.1982
Dennis A. Laska, Patricia D. Williams, John T. Reboulet, Robert M. Morris, The L6 muscle cell line as a tool to evaluate parenteral products for irritation. Pda Journal of Pharmaceutical Science and Technology. ,vol. 45, pp. 77- 82 ,(1991)
J. P. Blass, R. A. P. Kark, W. K. Engel, Clinical Studies of a Patient With Pyruvate Decarboxylase Deficiency JAMA Neurology. ,vol. 25, pp. 449- 460 ,(1971) , 10.1001/ARCHNEUR.1971.00490050083007
Leo T. Burka, Johniene Doran, Benjamin J. Wilson, Enzyme inhibition and the toxic action of moniliformin and other vinylogous α-ketoacids Biochemical Pharmacology. ,vol. 31, pp. 79- 84 ,(1982) , 10.1016/0006-2952(82)90240-4